Article Image

Pivotal ZOTRIP Study Shows Fast Freedom Rate from Migraine and Low 24-Hour Recurrence Rate

Op-Med is a collection of original articles contributed by Doximity members.
Image: Shutterstock

Phase two of the ZOTRIP study has revealed that the drug can provide 2-hour freedom rate, as well as a low 24-hour recurrence rate.

ZOTRIP contains zolmitriptan, which is considered a tried and true triptan that has been used for many years. It gained notoriety for its fast onset of pain relief and low headache recurrence from migraine. Using a novel and proprietary technology called Adhesive Dermally-Applied Microarray (ADAM), ZOTRIP is inserted underneath the skin layer.

“It’s an innovative technology that helps to bypass the G.I. tract,” said Dr. Alan Rapoport, a clinical professor of Neurology at the David Geffen School of Medicine at UCLA who presented the study recently at the 60th Annual Scientific Meeting for the American Headache Society. “Right now we have injections and nasal sprays for migraine, both of which work well and quickly. But some people don’t like either of them; this is a good alternative, going into the outer layer of skin, not hurting at all and not causing too many side effects.”

Dr. Rapoport noted very good 2-hour pain freedom rate of slightly over 41% and an excellent 24 and 48 hour low recurrence rate. 24-hour recurrence rate is about 15%.

“I expect when this is approved by the FDA and released, it will be a welcome addition to our migraine acute care armamentarium,” Dr. Rapoport said.

The study, “Rapid Systemic Absorption of Zolmitriptan from M207 is Associated with a High Rate of Pain Relief and a Low Incidence of Moderate or Severe Pain Recurrence,” was recently presented at the 60th Annual Scientific Meeting for the American Headache Society.

All opinions published on Op-Med are the author’s and do not reflect the official position of Doximity or its editors. Op-Med is a safe space for free expression and diverse perspectives. For more information, or to submit your own opinion, please see our submission guidelines or email

More from Op-Med